Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | +2.57% | -2.60% | +57.67% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.67% | 283M | |
+33.97% | 693B | |
+29.39% | 584B | |
-3.32% | 372B | |
+20.19% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.61% | 168B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating